SuperworthCigna CI
- Market cap
- $81.1B
- PE
- 12.7×
- 10y median 16.1×
- Forward PE
- 9.7×
- 10y median 11.4×
- Price to sales
- 0.3×
- EV/EBIT
- 10.4×
- Revenue, 12 months
- $282.4B
- +8% on a year ago
- Net margin
- 2.3%
- Free cash flow yield
- n/m
- not a meaningful number
Cigna trades at 12.7× trailing earnings, cheaper than 75% of the last ten years. Revenue was $282.4B over the last twelve months, up 8% on a year earlier with a 2% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $49B+8% | $51.1B+12% | $57.3B+23% | $60.5B+25% | $63.7B+30% | $65.6B+28% | $65.5B+14% | $67.2B+11% | $69.7B+10% | $72.5B+10% | $68.5B+5% | $71.7B+7% | |
| Cost of revenue | $33.6B+6% | $35.3B+10% | $41.4B+32% | $44.5B+33% | $47.6B+41% | $49B+39% | $48.4B+17% | $53.3B+20% | $55.5B+17% | $57.8B+18% | $54.1B+12% | $56.7B+6% |
| Gross profit | $15.4B+14% | $15.9B+16% | $15.8B+5% | $16B+6% | $16.1B+5% | $16.6B+5% | $17.1B+8% | $13.9B−13% | $14.2B−12% | $14.7B−12% | $14.4B−16% | $15B+8% |
| SG&A | $3.8B+20% | $4.1B+17% | $3.7B+5% | $3.7B+7% | $3.6B−5% | $3.9B−5% | $4.2B+14% | $3.4B−7% | $3.4B−6% | $3.6B−7% | $3.7B−12% | $3.5B+1% |
| $2.2B+5% | $2.1B+18% | $2.3B+12% | $2.4B+9% | $2.6B+15% | $2.2B+6% | $2B−13% | $2.3B−4% | $2.6B+0% | $2.3B+8% | $2.4B+20% | $2.7B+16% | |
| Interest expense | $353M+11% | $352M−0% | $369M+7% | $378M+8% | $380M+8% | $400M+14% | $362M−2% | $338M−11% | $363M−5% | $300M−25% | $357M−1% | $359M+6% |
| Pre-tax income | $1.8B−47% | $188M−86% | $79M−95% | $2B+6% | $1.2B−35% | $2B+969% | $1.6B+1986% | $2B+2% | $2.3B+93% | $1.8B−10% | $2.3B+38% | $2.3B+12% |
| $391M−45% | −$919M | $291M−1% | $360M−4% | $367M−6% | $473M | $239M−18% | $389M+8% | $322M−12% | $543M+15% | $409M+71% | $382M−2% | |
| Net income | $1.4B−49% | $1B−14% | −$277M | $1.5B+6% | $739M−48% | $1.4B+38% | $1.3B | $1.5B−1% | $1.9B+153% | $1.2B−13% | $1.7B+25% | $1.7B+8% |
| $4.74−47% | $3.49−11% | −$0.97 | $5.45+11% | $2.63−45% | $5.13+47% | $4.85 | $5.71+5% | $6.98+165% | $4.64−10% | $6.26+29% | $6.29+10% | |
| 297.1M−3% | 294.6M−4% | 286.5M−4% | 284.1M−4% | 281.4M−5% | 277.8M−6% | 273M−5% | 268.2M−6% | 267.5M−5% | 265.7M−4% | 264M−3% | 264M−2% |
Gross profit: 49 periods, Q1 FY11 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 7 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q1 FY11 to Q4 FY11: not printed by the filing, worked out from its own lines. 14 periods, Q4 FY12 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $72.6B | $70B to $73.4B | $7.52 | $7.50 to $7.54 | 15 |
| Q4 FY26 | $74.9B | $73.6B to $75.8B | $7.41 | $7.38 to $7.44 | 14 |
| Q1 FY27 | $71.5B | $69.1B to $73.1B | $8.33 | $7.96 to $8.58 | 8 |
| Q2 FY27 | $74B | $71.5B to $75.7B | $8.56 | $8.18 to $8.81 | 6 |
| Q3 FY27 | $75.7B | $73.1B to $77.4B | $8.38 | $8.02 to $8.63 | 6 |
| Q4 FY27 | $78.5B | $75.8B to $80.3B | $8.19 | $7.83 to $8.44 | 12 |
| Q1 FY28 | $75.9B | $73.4B to $77.7B | $9.24 | $8.84 to $9.52 | 13 |
| Q2 FY28 | $78.4B | $75.8B to $80.2B | $9.50 | $9.08 to $9.78 | 7 |
Peers
Companies in Medical - Healthcare Plans nearest Cigna's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CICigna | $81.1B | 12.7× | 16.1× | 9.7× | 0.3× | +8% | 2.3% |
| ELVElevance Health | $95.4B | 19.6× | 17.6× | 16.1× | 0.5× | +6% | 2.5% |
| CVSCVS Health | $119.5B | 24.7× | 16.2× | 11.5× | 0.3× | +7% | 1.2% |
| HUMHumana | $50.7B | 39.9× | 20.7× | 33.7× | 0.3× | +18% | 0.9% |
| CNCCentene | $34.7B | n/m | 20.7× | 15.0× | 0.2× | +14% | −2.5% |
| UNHUnitedHealth | $375.3B | 23.9× | 22.7× | 18.5× | 0.8× | +3% | 3.5% |
| OSCROscar Health | $9.6B | 22.3× | 47.9× | n/m | 0.6× | +43% | 3.6% |
| Peer median | $73B | 23.9× | 20.7× | 16.1× | 0.4× | +11% | 1.8% |
Investors who own it
Investors we follow who held Cigna at the end of Jun 30, 2026, from their 13F filings.
- David EinhornGreenlight Capital0.6% of portfolio
More on Cigna
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 51Healthcare stocks with the lowest forward PE
- #2of 10Health insurers with the lowest EV/EBIT
- #3of 11Health insurers with the lowest price to sales ratio
- #4of 11Health insurers with the highest profit margins
- #7of 11Health insurers with the fastest revenue growth
Its groups
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .